2 results
Approved WMOPending
Primary Objective- Compare the safety and efficacy of subcutaneous somavaratan and daily rhGH during 12 months of treatment.Secondary Objective-Evaluate and compare changes in pharmacodynamic responses (IGF-I, IGF binding protein-3 (IGFBP-3), growth…
Approved WMORecruiting
The primary objective is to assess the long-term safety of nemolizumab (CD14152) insubjects with prurigo nodularis (PN).The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152)in subjects with PN